Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2020 | The different care pathways for mild and severe Alzheimer’s disease

Clive Ballard • 24 Jul 2020
AAIC 2020
Alzheimer’s Disease Dementia

Clive Ballard, University of Exeter Medical School, Exeter, UK, talks about the disparity of care pathways available for dementia treatment. Prof. Ballard explains that enhanced and improved monitoring for mild cognitive impairment is needed to stop further deterioration. He proposes updated virtual solutions to tackle this issue. On the other hand, in cases of severe dementia, he dissuades the use of antipsychotics. This interview was recorded on an online conference call with The Video Journal of Dementia (VJDementia).

More from Clive Ballard

Repurposing existing drugs to treat Alzheimer's disease
3:54
Repurposing existing drugs to treat Alzheimer's disease
Clive Ballard • 24 Jul 2020
The importance of early treatment and diagnosis of Alzheimer's disease
2:02
The importance of early treatment and diagnosis of Alzheimer's disease
Clive Ballard • 24 Jul 2020
Alzheimer's disease: balancing infection risk and mental well-being during the COVID-19 pandemic
2:43
Alzheimer's disease: balancing infection risk and mental well-being during the COVID-19 pandemic
Clive Ballard • 24 Jul 2020
Dementia program at University of Exeter Medical School
1:38
Dementia program at University of Exeter Medical School
Clive Ballard • 24 Jul 2020

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals